全文获取类型
收费全文 | 1747篇 |
免费 | 142篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 77篇 |
妇产科学 | 28篇 |
基础医学 | 139篇 |
口腔科学 | 33篇 |
临床医学 | 214篇 |
内科学 | 478篇 |
皮肤病学 | 22篇 |
神经病学 | 101篇 |
特种医学 | 338篇 |
外科学 | 121篇 |
综合类 | 65篇 |
预防医学 | 113篇 |
眼科学 | 24篇 |
药学 | 53篇 |
中国医学 | 9篇 |
肿瘤学 | 72篇 |
出版年
2022年 | 6篇 |
2021年 | 9篇 |
2020年 | 16篇 |
2019年 | 20篇 |
2018年 | 33篇 |
2017年 | 17篇 |
2016年 | 18篇 |
2015年 | 30篇 |
2014年 | 61篇 |
2013年 | 92篇 |
2012年 | 66篇 |
2011年 | 74篇 |
2010年 | 66篇 |
2009年 | 88篇 |
2008年 | 68篇 |
2007年 | 82篇 |
2006年 | 62篇 |
2005年 | 68篇 |
2004年 | 62篇 |
2003年 | 38篇 |
2002年 | 55篇 |
2001年 | 27篇 |
2000年 | 29篇 |
1999年 | 31篇 |
1998年 | 86篇 |
1997年 | 58篇 |
1996年 | 68篇 |
1995年 | 48篇 |
1994年 | 54篇 |
1993年 | 47篇 |
1992年 | 21篇 |
1991年 | 14篇 |
1990年 | 25篇 |
1989年 | 50篇 |
1988年 | 33篇 |
1987年 | 36篇 |
1986年 | 29篇 |
1985年 | 17篇 |
1984年 | 20篇 |
1983年 | 15篇 |
1982年 | 18篇 |
1981年 | 25篇 |
1980年 | 15篇 |
1979年 | 8篇 |
1978年 | 11篇 |
1977年 | 16篇 |
1976年 | 10篇 |
1975年 | 12篇 |
1973年 | 5篇 |
1971年 | 4篇 |
排序方式: 共有1898条查询结果,搜索用时 15 毫秒
91.
Maternal Vitamin D Status During Pregnancy and Bone Mass in Offspring at 20 Years of Age: A Prospective Cohort Study
下载免费PDF全文
![点击此处可从《Journal of bone and mineral research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Kun Zhu Jenny Mountain Stephen Lye Craig Pennell John P Walsh 《Journal of bone and mineral research》2014,29(5):1088-1095
It is uncertain whether the vitamin D status of pregnant women influences bone mass of their children. Cohort studies have yielded conflicting results; none have examined offspring at skeletal maturity. This longitudinal, prospective study investigated the association between maternal vitamin D status and peak bone mass of offspring in 341 mother and offspring pairs in the Western Australian Pregnancy Cohort (Raine) Study. Maternal serum samples collected at 18 weeks gestation were assayed for 25‐hydroxyvitamin D (25OHD). Outcomes were total body bone mineral content (BMC) and bone mineral density (BMD) measured by dual‐energy X‐ray absorptiometry in offspring at 20 years of age. The mean (± SD) maternal serum 25OHD concentration was 57.2 ± 19.2 nmol/L; 132 women (38.7%) were vitamin D‐deficient (25OHD <50 nmol/L). After adjustment for season of sample collection, maternal factors, and offspring factors (sex, birth weight, and age, height, lean mass, and fat mass at 20 years), maternal 25OHD concentration was positively associated with total body BMC and BMD in offspring, with a mean difference of 19.2 (95% confidence interval [CI], 5.6–32.7) g for BMC and 4.6 (95% CI, 0.1–9.1) mg/cm2 for BMD per 10.0 nmol/L of maternal 25OHD. Maternal vitamin D deficiency was associated with 2.7% lower total body BMC (mean ± SE) (2846 ± 20 versus 2924 ± 16 g, p = 0.004) and 1.7% lower total body BMD (1053 ± 7 versus 1071 ± 5 mg/cm2, p = 0.043) in the offspring. We conclude that vitamin D deficiency in pregnant women is associated with lower peak bone mass in their children. This may increase fracture risk in the offspring in later life. © 2014 American Society for Bone and Mineral Research. 相似文献
92.
由于治疗方法的进步,近80%的儿童和青少年癌症患者能够长期生存。在美国,约有270000例儿童癌症的幸存者,即每640名20至39岁成年人中就有一名幸存者。大量的幸存者有利于儿童癌症治疗后长期健康结果的研究。现在可以明确的是,化疗和放疗所致的儿童各器官系统损害在临床上可能潜伏多年。为了全面了解治疗儿童癌症而继发的健康问题,重要的是衡量三项长期结果:健康状况、死亡率和患病率。这三项中,关于前两项已有相当好的研究报道。在一项对20227例癌症5年生存者的回顾性分析中,Mertens等发现以下原因导致的超额死亡率具有统计学意义:继发癌症(… 相似文献
93.
N G Bellenger M I Burgess S G Ray A Lahiri A J Coats J G Cleland D J Pennell 《European heart journal》2000,21(16):1387-1396
AIMS: To prospectively compare the agreement of left ventricular volumes and ejection fraction by M-mode echocardiography (echo), 2D echo, radionuclide ventriculography and cardiovascular magnetic resonance performed in patients with chronic stable heart failure. It is important to know whether the results of each technique are interchangable, and thereby how the results of large studies in heart failure utilizing one technique can be applied using another. Some studies have compared cardiovascular magnetic resonance with echo or radionuclude ventriculography but few contain patients with heart failure and none have compared these techniques with the current fast breath-hold acquisition cardiovascular magnetic resonance. METHODS AND RESULTS: Fifty two patients with chronic stable heart failure taking part in the CHRISTMAS Study, underwent M-mode echo, 2D echo, radionuclude ventriculography and cardiovascular magnetic resonance within 4 weeks. The scans were analysed independently in blinded fashion by a single investigator at three core laboratories. Of the echocardiograms, 86% had sufficient image quality to obtain left ventricular ejection fraction by M-mode method, but only 69% by 2D Simpson's biplane analysis. All 52 patients tolerated the radionuclude ventriculography and cardiovascular magnetic resonance, and all these scans were analysable. The mean left ventricular ejection fraction by M-mode cube method was 39+/-16% and 29+/-15% by Teichholz M-mode method. The mean left ventricular ejection fraction by 2D echo Simpson's biplane was 31+/-10%, by radionuclude ventriculography was 24+/-9% and by cardiovascular magnetic resonance was 30+/-11. All the mean left ventricular ejection fractions by each technique were significantly different from all other techniques (P<0.001), except for cardiovascular magnetic resonance ejection fraction and 2D echo ejection fraction by Simpson's rule (P=0.23). The Bland-Altman limits of agreement encompassing four standard deviations was widest for both cardiovascular magnetic resonance vs cube M-mode echo and cardiovascular magnetic resonance vs Teichholz M-mode echo at 66% each, and was 58% for radionuclude ventriculography vs cube M-mode echo, 44% for cardiovascular magnetic resonance vs Simpson's 2D echo, 39% for radionuclide ventriculography vs Simpson's 2D echo, and smallest at 31% for cardiovascular magnetic resonance-radionuclide ventriculography. Similarly, the end-diastolic volume and end-systolic volume by 2D echo and cardiovascular magnetic resonance revealed wide limits of agreement (52 ml to 216 ml and 11 ml to 188 ml, respectively). CONCLUSION: These results suggest that ejection fraction measurements by various techniques are not interchangeable. The conclusions and recommendations of research studies in heart failure should therefore be interpreted in the context of locally available techniques. In addition, there are very wide variances in volumes and ejection fraction between techniques, which are most marked in comparisons using echocardiography. This suggests that cardiovascular magnetic resonance is the preferred technique for volume and ejection fraction estimation in heart failure patients, because of its 3D approach for non-symmetric ventricles and superior image quality. 相似文献
94.
Cristina Mei Joanna Fitzsimons Nicholas Allen Mario Alvarez‐Jimenez Günter Paul Amminger Vivienne Browne Mary Cannon Maryann Davis Barbara Dooley Ian B. Hickie Srividya Iyer Ein Killackey Ashok Malla Ian Manion Steve Mathias Kerryn Pennell Rosemary Purcell Debra Rickwood Swaran P. Singh Stephen J. Wood Alison Yung Patrick D. McGorry 《Early intervention in psychiatry》2020,14(1):3-13
95.
Jared M. Weiss MD Nathan Pennell MD PhD Allison M. Deal MS Daniel Morgensztern MD Daniel S. Bradford MD Jeffrey Crane MD Howard Jack West MD Carrie Lee MD Chad Pecot MD James P. Stevenson MD William Irvin MD Mark Socinski MD Tom Stinchcombe MD Liza C. Villaruz MD Hyman B. Muss MD 《Cancer》2020,126(5):1060-1067
96.
Jose Lopez-Sendon Peter Mills Heinz Weber Rolf Michels Carlo Di Mario Gerasimos S Filippatos Magda Heras Kevin Fox Jose Merino D J Pennell Heinz Sochor Joanna Ortoli Andras Szatmari Fausto Pinto Jan Peder Amlie Ali Oto Mitja Lainscak Kim Fox Peter Kearney Lino Gon?alves Heikki Huikuri Celine Carrera 《European heart journal》2007,28(17):2163-2171
97.
98.
99.
IntroductionThe epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib was recently approved for resected EGFR-mutant stages IB-IIIA non-small cell lung cancer due to improved disease-free survival (DFS) in this population compared with placebo. This study aimed to evaluate the cost-effectiveness (CE) of this strategy.Materials and MethodsWe constructed a Markov model using post-resection health state transitions with digitized DFS data from the ADAURA trial to compare cost and quality-adjusted life years (QALYs) of 3 years of adjuvant osimertinib versus placebo over a 10-year time horizon. An overall survival (OS) benefit of 5% was assumed. Costs and utility values were derived from Medicare reimbursement data and literature. A CE threshold of 3 times the gross domestic product per capita was used. Sensitivity analyses were performed.ResultsThe incremental cost-effectiveness ratio for adjuvant osimertinib was $317 119 per QALY-gained versus placebo. Initial costs of osimertinib are higher in years 1-3. Costs due to progressive disease (PD) are higher in the placebo group through the first 6.5 years. Average pre-PD, post-PD, and total costs were $2388, $379 047, and $502 937, respectively, in the placebo group, and $505 775, $255 638, and $800 697, respectively, in the osimertinib group. Sensitivity analysis of OS gains reaches CE with an hazard ratio (HR) of 0.70-0.75 benefit of osimertinib over placebo. A 50% discount to osimertinib drug cost yielded an ICER of $115 419.ConclusionsThree-years of adjuvant osimertinib is CE if one is willing to pay $317 119 more per QALY-gained. Considerable OS benefit over placebo or other economic interventions will be needed to reach CE. 相似文献
100.